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Aims: Endothelin receptor A (ETA) antagonism normalizes fetal growth in several models of rodent fetal
growth restriction (FGR). Our aims were to determine the levels of ETA antagonist in maternal and fetal plas-
ma following chronic maternal administration, and to determine its impact on pregnancy outcome, survival
and growth of rat pups.
Main methods: Timed pregnant rats were treated with one of two endothelin receptor antagonists or vehicle,
from gestation day 14–21 (term=22 days). The antagonists and their respective doses were ABT-546
(20 mg/kg/day) and FR139317 (12 mg/kg/day). On day 21, in six rats per group, maternal and fetal plasma
ABT-546 was assayed by HPLC. Five additional rats in each group delivered spontaneously and nursed their
pups through postpartum day 7. Viability of newborns, oxygen saturation, litter sizes, and pup weights
were recorded on postpartum days 1 and 7.
Key ﬁndings: Fetal antagonist levels reached only 2% of maternal levels (pb0.01). There were no signiﬁcant
differences among groups in length of gestation; litter size; survival, number and weight of live pups at
birth and at 7 days postpartum; and tissue oxygen saturation.
Signiﬁcance: Maternal administration of an ETA antagonist, at a dose sufﬁcient to ameliorate FGR, has no adverse
impact on survival and growth of neonatal rat pups. ETA antagonism, delivered maternally, produces sufﬁciently
low fetal plasma levels of antagonist so as not to present a survival threat to theneonatal pups. The beneﬁcial effects
of maternally administered ETA antagonism on fetal growth occur in the ma© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Fetal growth restriction (FGR) is a common and important cause
of perinatal morbidity and mortality (McIntire et al., 1999; Lackman
et al., 2001; Bernstein et al., 2000). This is particularly true when
growth restriction complicates a pregnancy remote from term
(Garite et al., 2004). Suboptimal uterine and placental perfusion is
the most commonly identiﬁable cause of FGR.
Endothelin-1 (ET-1), a vasoactive mediator produced primarily by
endothelial cells, is one of the most potent endogenous vasoconstric-
tors known and, along with its receptors, is expressed in the placenta.
ET-1 infusion in maternal rats results in FGR independent of maternal
hypertension (Neerhof et al., 1997). ET-1 has also been shown to have
a primary role in the pathophysiology of several other rat models ofl Medicine, Department of Ob-
uite 1507, Evanston, IL 60201,
).
-NC-ND license.FGR. The involvement of ET-1 was investigated using endothelin re-
ceptor A (ETA) antagonism, which normalized fetal growth in each
case. These include amelioration of FGR by ETA antagonism in the set-
ting of hypoxia (Thaete et al., 1997), nitric oxide synthase inhibition
(Thaete et al., 2001), and unilateral uterine ischemia/reperfusion
(Thaete & Neerhof, 2006). The primary physiologic mechanism by
which FGR is prevented in each of these settings is restoration of ad-
equate blood ﬂow to the placenta (Thaete et al., 2004, 2005).
While ETA antagonism has been effective to ameliorate FGR in these
animals models, direct administration of ETA antagonists to newborn
rats within three hours of delivery has been consistently associated
with neonatal demise (Taniguchi & Muramatsu, 2003). This was due
to failure of the ductus arteriosus to close, a process that is known to in-
volve the action of ET-1 (Taniguchi & Muramatsu, 2003; Coceani et al.,
1992) — reviewed by Perreault & Coceani (Perreault & Coceani, 2003).
These reports raise concerns about the safety of the use of ETA antago-
nists late in human pregnancy to address FGR clinically.
Before ETA antagonism can be considered seriously for therapeutic
intervention in human pregnancy, the impact of the antagonists in
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exposure to ETA antagonists (by maternal administration in late ges-
tation) and its impact on rat pup survival and oxygen saturation has
not been investigated. Further, the relative plasma levels of ETA an-
tagonist in maternal and fetal circulations following maternal admin-
istration are not known. The goals of the experiments reported herein
were to determine the impact of maternally administered ETA antag-
onist on pregnancy outcome, survival, growth, and oxygen saturation
in neonatal rats. We also measured the maternal and fetal plasma
levels of ETA antagonist at term following chronic maternal adminis-
tration during the ﬁnal third of pregnancy.
Materials and methods
Endothelin receptor antagonists
ABT-546 is a nonpeptide carboxylic acid derivativewith a high afﬁn-
ity for ETA receptors (Ki=0.46 nM) and a low afﬁnity for ETB receptors
(Ki=13 000 nM) (Wu-Wong et al., 1999). FR139317 is a tripeptide that
exhibits high-afﬁnity binding to ETA (Ki=1.0 nM) and low-afﬁnity
binding to ETB (Ki=7300 nM) (Sogabe et al., 1993; Opgenorth, 1995).
Animals and treatment
Nonpregnant Sprague-Dawley female andmale ratswere purchased
fromHarlan Laboratories (Madison,WI), housed in theNorthShore Uni-
versity HealthSystem Research Institute Center for Comparative Medi-
cine, maintained on 12-h light/dark cycles, and allowed free access to
a standard laboratory rodent diet and water. Animal care and the con-
duct of all experiments were approved by the NorthShore University
HealthSystem Research Institute Animal Care and Use Committee.
Rats were bred at an age of 11–20 weeks and a weight of 225–250 g.
Timed-pregnant Sprague-Dawley rats in separate groups were
treated with ABT-546 (20 mg/kg/day), FR139317 (12 mg/kg/day), or
their vehicle (20% ethanol, 40% propylene glycol, and 0.04 M NaOH
in H2O, or 4.2% NaHCO3, respectively) by a subcutaneous 2-ml osmot-
ic pump. The doses used are at the high end of the range of effective
doses that restore normal fetal growth in several rat models of fetal
growth restriction (Thaete et al., 1997, 2001). The high end of the ef-
fective dose range was chosen in order better to evaluate the full im-
pact of these ETA antagonists in normal pregnancy outcome. For
FR139317, the pump was connected to an intravenous catheter (infu-
sion rate=10 μl/h). On day 14 of a 22-day gestation, under general
anesthesia consisting of a single IP injection of ketamine 40 mg/kg,
xylazine 8 mg/kg, and acepromazine 1.3 mg/kg in combination, an in-
dwelling catheter (Tygon, outer diameter=0.76 mm, Saint-Gobain,
Akron, OH) was placed into the left jugular vein and then tunneled
subcutaneously to the back of the neck for osmotic pump attachment.
Infusion of each antagonist (ABT-546 or FR139317) or vehicle contin-
ued from gestation day 14 through day 21, at which time the pumps
were removed from the rats which delivered their pups (see next
paragraph) so as not to continue the antagonist treatment during
the postnatal period.
Measurement of physiologic parameters
Five pregnant rats in each group were allowed to deliver sponta-
neously and to nurse their pups through post-partum day 7. Viability
of newborns, litter sizes, and pup weights were recorded soon after
birth (postpartum day 1) and at day 7. Oxygen saturation of each
rat pup was measured non-invasively using a MouseOx pulse oxime-
ter (Starr Life Sciences, Oakmont, PA) on postpartum days 1 and 7.
Results are presented as means±SE. Statistical analysis was by anal-
ysis of variance followed by a post hoc Newman-Keuls test, with
pb0.05 considered statistically signiﬁcant.ABT-546 plasma determination
In separate groups of six timed-pregnant rats treated with ABT-
546 or vehicle from gestation day 14 through 21, dams were eutha-
nized on day 21 and maternal blood was collected from the vena
cava. Fetal blood was obtained by incision across the neck at the jug-
ular vein and was pooled for each litter. Blood was collected into
tubes containing ethylenediaminetetra-acetic acid and centrifuged
at 14000 g to collect plasma. The peptide FR139317 is not being pro-
posed for clinical use, whereas synthetic compounds such as ABT-546
are candidates for clinical use, therefore only ABT-546 plasma levels
were measured in this study.
Maternal and fetal plasma was assayed for ABT-546 levels as fol-
lows. ABT-546 and the internal standard were separated from plasma
using liquid–liquid extraction with tert-butylmethylether (TBME). In
detail, a 200 μl plasma sample or spiked standard was combined with
50 μl internal standard (structurally related compound prepared in
acetonitrile:water (1:1, by volume)), 900 μl TBME and 50 μl 1 N HCl.
Following votex mixing and centrifugation (2000 rpm×10 min,
4 °C), 800 μl of the organic layer was transferred in an automated
manner (Tomtec Quadra™) to a clean 96-well plate and evaporated
to dryness on a Micro-Vap™ under a stream of nitrogen at 35 °C. Sam-
ples were reconstituted by vortexing with 200 μl mobile phase. Sam-
ples were analyzed simultaneously with spiked plasma standards.
ABT-546 and the internal standard were separated from co-
extracted contaminants on a 50×3 mm 5 μm Betasil CN column
(Thermo), with an acetonitrile and 0.1% triﬂuoroacetic acid mobile
phase (56:34, by volume) at a ﬂow rate of 0.4 ml/min. Analysis was
performed on an API 2000 (Applied Biosystems), with a TurboIon-
Spray interface. Analytes were ionized in the positive ion mode with
a source temperature of approximately 450 °C. Detection was in the
multiple reaction monitoring mode at mass-to-charge ratio (m/z)
553.3→376.1 for ABT-546 and m/z 559.2→107.0 for the internal
standard. ABT-546 and internal standard peak areas were determined
using Sciex TurboQuan™ software. The plasma drug concentration of
each sample was calculated by least squares linear regression analysis
of the peak area ratio (parent / internal standard) of the spiked plas-
ma standards versus concentration. The standard curve over the con-
centration range 8–1542 ng/ml had a mean accuracy of 91.2–114.3%
and CV b6.5% for the analysis of triplicate standards at six separate
concentrations; the limit of quantitation was estimated to be ~5 ng/
ml. Results are presented as mean±SE. Statistical analysis was by
paired samples t test, with pb0.05 considered statistically signiﬁcant.
Results
There was no difference in outcomes between the control groups
receiving the respective vehicles, therefore these groups are reported
as a single vehicle group.
All animals delivered their pups at the normally expected time for
parturition (Fig. 1A). The gestation day of delivery was in a tight
range of 21.5–22.5 days across all experimental groups.
Litter sizes for all groups were similar and not signiﬁcantly different
from each other (Fig. 1B). This parameter included all live and stillborn
pups. Very few stillbirths occurred in any of the groups and there was
no signiﬁcant difference among groups with respect to this parameter.
The mean±SE of stillbirth occurrence was: 6.0±3.0; 7.7±3.9; and
1.6±1.6 (vehicle, FR139317, and ABT-546, respectively).
There were no signiﬁcant differences among the groups with
respect to the number of live pups per litter at birth (Fig. 1C). Neither
was there a difference in the number of pups surviving at postnatal
day 7 (Fig. 1D) and this number did not differ from the number of
live pups at birth.
Birth weights were similar among rats in all groups (Fig. 1E). Rat
pups in all experimental groups appeared to thrive and the weights
of the pups in all groups at postnatal day 7 (Fig. 1F) were similar.
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Fig. 1. Pregnancy outcomes and physiologic parameters measured in rat pups at postnatal days 1 and 7 (n=5 litters in all groups) exhibit a normal proﬁle after 7-day maternal
treatment with ETA antagonists. Panel A: Parturition occurred at normal term of approximately 22 days. Panel B: The number of pups in each litter (live+stillborn pups) did not
differ among groups. Panel C: The number of live pups per litter did not differ among groups. Panel D: The number of live pups at postnatal day 7 was not different among
experimental groups. Postnatal deaths were extremely rare and the numbers of live pups at postnatal days 1 and 7 did not differ signiﬁcantly. Panel E: Rat pup weights at birth
did not differ among groups. Panel F: Pup weights at postnatal day 7 did not differ among groups.
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Fig. 2. Tissue oxygen saturation (n=5 litters in all groups) determined non-invasively
by pulse oximeter was not signiﬁcantly different among any of the experimental
groups at postnatal day 1. At postnatal day 7, neonates from ABT-546-treated dams
exhibited a signiﬁcantly higher oxygen saturation compared with vehicle-treated
controls and pups from FR139317-treated dams.
585L.G. Thaete et al. / Life Sciences 91 (2012) 583–586Oxygen saturation was the same for neonatal pups in all groups on
postnatal day 1 (Fig. 2). Oxygen saturation at postnatal day 7 was not
lower than control levels in any group but was signiﬁcantly higher in
the ABT-546-treated group (Fig. 2).
Plasma concentrations of the ETA receptor antagonist ABT-546
(Fig. 3) in fetal plasma averaged only 2% of those in maternal plasma
(pb0.01) on gestation day 21. Maternal plasma ABT-546 concentra-
tions ranged from 0.45 to 1.30 μg/ml and fetal plasma concentrations
were in a range of 0.012 to 0.023 μg/ml. The ratio of maternal/fetal
plasma antagonist concentrations had a range of 23.2 to 103.4 follow-
ing maternal administration of ABT-546 for 7 days.
Discussion
The need for a therapeutic modality to address fetal growth re-
striction is especially imperative considering the fact that no such
treatment option exists at this time. This is the case in spite of numer-
ous investigations into this obstetric complication that can be life-
threatening for both mother and fetus. We have shown for the ﬁrst
time that the use of ETA antagonism in late pregnancy, after organo-
genesis is complete, yields a normal proﬁle of several physiologic pa-
rameters in neonatal rats. Additionally, maternal blood pressures,
which were not measured in this study, decreased 7–13% in response
to ETA antagonists compared to vehicle in previous studies in our lab-
oratory with normal pregnant rats (Thaete & Neerhof, 2000). Asdemonstrated by the current study, this moderate change in blood
pressure did not prevent normal maternal nurturing or normal thriv-
ing for the pups. The results reported in this paper, combined with
Plasma Concentrations of 
ABT-546
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
m
ic
ro
gr
am
s 
/ m
l
Maternal   Fetal
**
Fig. 3.Maternal and fetal plasma concentrations of ABT-546 at gestation day 21 (n=6
litters in each group) were highly signiﬁcantly different, demonstrating the limited
access that the antagonist has across the placenta from the maternal to the fetal
compartment. **pb0.01 by paired samples t test.
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tagonism in several models of growth restriction (Thaete et al., 1997,
2001; Thaete & Neerhof, 2006), provides increasing conﬁdence that
ETA antagonists may be clinically applicable to address human FGR.
We have tested two different ETA antagonists that are members of
two distinct classes of compounds, namely, a peptide and a non-
peptide carboxylic acid derivative. The results presented herein are,
therefore, not compound-speciﬁc and demonstrate that antagonists
composed of different chemical structures, but exhibiting similar
receptor-speciﬁc activities, produce the same outcome in normal rat
pregnancy.
Endothelin is actively involved in the closure of the ductus arterio-
sus soon after birth (Coceani et al., 1992; Taniguchi et al., 2001),
shunting blood to the lungs instead of to the umbilical circulation. It
has been reported that direct IP administration of an ETA antagonist
to neonatal rats was fatal due to failure of the ductus arteriosus to
close (Taniguchi & Muramatsu, 2003). In contrast, the study reported
herein involved only maternal administration of the ETA antagonists,
not direct administration to the fetuses or neonates. The normal oxy-
genation data in newborn rat pups presented here demonstrates
appropriate closure of the ductus. This in combination with the dem-
onstration that fetal plasma levels of antagonist reach only 2% of ma-
ternal levels shows that maternal administration of these compounds
prevents the fetus from receiving a sufﬁcient dose to endanger ductus
closure. Direct neonatal administration of antagonist is to be avoided;
but this would never become an issue when addressing human FGR
because treatment with an ETA antagonist to address FGR would beconducted during late pregnancy, via maternal administration. The
dramatic maternal–fetal difference in plasma antagonist levels
shows that the amount of antagonist that crosses the placenta and
that can be available to affect fetal growth or neonatal well-being im-
mediately after birth is effectively limited.
Conﬂict of interest statement
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Conclusions
Maternal administration of an ETA antagonist from gestation day
14 through parturition, at a dose sufﬁcient to ameliorate fetal
growth restriction, has no adverse impact on survival, growth, and
oxygen saturation in neonatal rat pups. Maternally administered
ETA antagonist has limited access across the placenta into the fetal
compartment, therefore ETA antagonism, delivered maternally, pro-
duces sufﬁciently low fetal plasma levels of antagonist so as not to
present a survival threat to the neonatal pups. The beneﬁcial effects
of ETA antagonism on fetal growth occur in the maternal, not the
fetal, compartment.
References
Bernstein IM, Horbar JD, Badger GJ, Ohlsson A, Golan A. Morbidity and mortality among
very-low-birth-weight neonates with intrauterine growth restriction. Am J Obstet
Gynecol 2000;182:198–206.
Coceani F, Kelsey L, Seidlitz E. Evidence for an effector role of endothelin in closure of
the ductus arteriosus at birth. Can J Physiol Pharmacol 1992;70:1061–4.
Garite TJ, Clark R, Thorp JA. Intrauterine growth restriction increases morbidity and
mortality among premature neonates. Am J Obstet Gynecol 2004;191:481–7.
Lackman F, Capewell V, Richardson B, daSilva O, Gagnon R. The risks of spontaneous
preterm delivery and perinatal mortality in relation to size at birth according to
fetal versus neonatal growth standards. Am J Obstet Gynecol 2001;184:946–53.
McIntire DD, Bloom SL, Casey BM, Leveno KJ. Birth weight in relation to morbidity and
mortality among newborn infants. New Engl J Med 1999;340:1234–8.
Neerhof MG, Silver RK, Caplan MS, Thaete LG. Endothelin-1-induced placental and fetal
growth restriction in the rat. J Matern Fetal Med 1997;6:125–8.
Opgenorth TJ. Endothelin receptor antagonism. Adv Pharmacol 1995;33:1-65.
Perreault T, Coceani F. Endothelin in the perinatal circulation. Can J Physiol Pharmacol
2003;81:644–53.
Sogabe K, Nirei H, Shoubo M, Nomoto A, Ao S, Notsu Y, et al. Pharmacological proﬁle of
FR139317, a novel, potent endothelin ETA receptor antagonist. J Pharmacol Exp
Ther 1993;264:1040–6.
Taniguchi T, Muramatsu I. Pharmacological knockout of endothelin ETA receptors. Life
Sci 2003;74:405–9.
Taniguchi T, Azuma H, Okada Y, Naiki H, Hollenberg MD, Muramatsu I. Endothelin-1-
endothelin receptor type A mediates closure of rat ductus arteriosus at birth. J
Physiol 2001;537:579–85.
Thaete LG, Neerhof MG. Endothelin and blood pressure regulation in the female rat:
Studies in normal pregnancy and with nitric oxide synthase inhibition-induced
hypertension. Hypertens Pregnancy 2000;19:233–47.
Thaete LG, Neerhof MG. Endothelin and platelet-activating factor: Signiﬁcance in the
pathophysiology of ischemia/reperfusion-induced fetal growth restriction in the
rat. Am J Obstet Gynecol 2006;194:1377–83.
Thaete LG, Neerhof MG, Caplan MS. Endothelin receptor A antagonism prevents
hypoxia-induced intrauterine growth restriction in the rat. Am J Obstet Gynecol
1997;176:73–6.
Thaete LG, Neerhof MG, Silver RK. Differential effects of endothelin A and B receptor
antagonism on fetal growth in normal and nitric oxide-deﬁcient rats. J Soc Gynecol
Investig 2001;8:18–23.
Thaete LG, Dewey ER, Neerhof MG. Endothelin and the regulation of uterine and
placental perfusion in hypoxia-induced fetal growth restriction. J Soc Gynecol
Investig 2004;11:16–21.
Thaete LG, Kushner DM, Dewey ER, Neerhof MG. Endothelin and the regulation of
uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth
restriction. Placenta 2005;26:242–50.
Wu-Wong JR, Dixon DB, Chiou WJ, Dayton BD, Novosad EI, Adler AL, et al. Pharmacol-
ogy of A-216546: a highly selective antagonist for endothelin ETA receptor. Eur J
Pharmacol 1999;366:189–201.
